Reproductive and Developmental Biology

The Korean Society of Animal Reproduction (한국동물번식학회)
권호 표지
DOI QR코드

DOI QR Code

The Laying Hen: An Animal Model for Human Ovarian Cancer

  • Lee, Jin-Young (WCU Biomodulation Major, Department of Agricultural Biotechnology, Seoul National University) ;
  • Song, Gwonhwa (WCU Biomodulation Major, Department of Agricultural Biotechnology, Seoul National University)
  • Received : 2013.03.08
  • Accepted : 2013.03.13
  • Published : 2013.03.31
Download PDF
⟨ Previous Next ⟩

Abstract

Ovarian cancer is the most lethal world-wide gynecological disease among women due to the lack of molecular biomarkers to diagnose the disease at an early stage. In addition, there are few well established relevant animal models for research on human ovarian cancer. For instance, rodent models have been established through highly specialized genetic manipulations, but they are not an excellent model for human ovarian cancer because histological features are not comparable to those of women, mice have a low incidence of tumorigenesis, and they experience a protracted period of tumor development. However, the laying hen is a unique and highly relevant animal model for research on human ovarian cancer because they spontaneously develop epithelial cell-derived ovarian cancer (EOC) as occurs in women. Our research group has identified common histological and physiological aspects of ovarian tumors from women and laying hens, and we have provided evidence for several potential biomarkers to detect, monitor and target for treatment of human ovarian cancers based on the use of both genetic and epigenetic factors. Therefore, this review focuses on ovarian cancer of laying hens and relevant regulatory mechanisms, based on genetic and epigenetic aspects of the disease in order to provide new information and to highlight the advantages of the laying hen model for research in ovarian carcinogenesis.

Keywords

References

  1. Ahn SE, Choi JW, Rengaraj D, Seo HW, Lim W, Han JY, Song G (2010): Increased expression of cysteine cathepsins in ovarian tissue from chickens with ovarian cancer. Reprod Biol Endocrinol 8:100. https://doi.org/10.1186/1477-7827-8-100
  2. Annunziata CM, Azad N, Dhamoon AS, Whiteley G, Kohn, EC (2008): Ovarian cancer in the proteomics era. Int J Gynecol Cancer 18 Suppl 1:1-6.
  3. Ansenberger K, Zhuge Y, Lagman JA, Richards C, Barua A, Bahr JM, Hales DB (2009): E-cadherin expression in ovarian cancer in the laying hen, Gallus domesticus, compared to human ovarian cancer. Gynecol Oncol 113:362-369. https://doi.org/10.1016/j.ygyno.2009.02.011
  4. Auersperg N (2011): The origin of ovarian carcinomas: a unifying hypothesis. Int J Gynecol Pathol 30: 12-21. https://doi.org/10.1097/PGP.0b013e3181f45f3e
  5. Auersperg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC (1998): The biology of ovarian cancer. Semin Oncol 25:281-304.
  6. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC (2001): Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22: 255-288.
  7. Balch C, Fang F, Matei DE, Huang TH, Nephew KP (2009): Minireview: epigenetic changes in ovarian cancer. Endocrinology 150:4003-4011. https://doi.org/10.1210/en.2009-0404
  8. Barua A, Bitterman P, Abramowicz JS, Dirks AL, Bahr JM, Hales DB, Bradaric MJ, Edassery SL, Rotmensch J, Luborsky JL (2009): Histopathology of ovarian tumors in laying hens: a preclinical model of human ovarian cancer. Int J Gynecol Cancer 19:531-539. https://doi.org/10.1111/IGC.0b013e3181a41613
  9. Bast RC Jr, Hennessy B, Mills GB (2009): The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9:415-428. https://doi.org/10.1038/nrc2644
  10. Bocker W (2002): [WHO classification of breast tumors and tumors of the female genital organs: pathology and genetics]. Verh Dtsch Ges Pathol 86: 116-119.
  11. Bovicelli A, D'Andrilli G, Giordano A (2011): New players in ovarian cancer. J Cell Physiol 226: 2500-2504. https://doi.org/10.1002/jcp.22662
  12. Brewer M, Ranger-Moore J, Satterfield W, Hao Z, Wang J, Brewer E, Wharton JT, Bast R, Zou C (2007): Combination of 4-HPR and oral contraceptive in monkey model of chemoprevention of ovarian cancer. Front Biosci 12:2260-2268. https://doi.org/10.2741/2228
  13. Cho KR, Shih Ie M (2009): Ovarian cancer. Annu Rev Pathol 4:287-313. https://doi.org/10.1146/annurev.pathol.4.110807.092246
  14. Cooke MS, Evans MD, Dizdaroglu M, Lunec J (2003): Oxidative DNA damage: mechanisms, mutation, disease. FASEB J 17:1195-1214. https://doi.org/10.1096/fj.02-0752rev
  15. D'Andrilli G, Kumar C, Scambia G, Giordano A (2004): Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies. Clin Cancer Res 10:8132-8141. https://doi.org/10.1158/1078-0432.CCR-04-0886
  16. Dahiya N, Sherman-Baust CA, Wang TL, Davidson B, Shih Ie M, Zhang Y, Wood W 3rd, Becker KG, Morin PJ (2008): MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 3:e2436. https://doi.org/10.1371/journal.pone.0002436
  17. Enomoto T, Weghorst CM, Inoue M, Tanizawa O, Rice JM (1991): K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 139:777-785.
  18. Fathalla MF (1971): Incessant ovulation-a factor in ovarian neoplasia? Lancet 2:163.
  19. Flesken-Nikitin A, Choi KC, Eng JP, Shmidt EN, Nikitin AY (2003): Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 63: 3459-3463.
  20. Fredrickson TN (1987): Ovarian tumors of the hen. Environ Health Perspect 73:35-51. https://doi.org/10.1289/ehp.877335
  21. Gregson RL, Lewis DJ, Abbott DP (1984): Spontaneous ovarian neoplasms of the laboratory rat. Vet Pathol 21:292-299. https://doi.org/10.1177/030098588402100305
  22. Hatziapostolou M, Iliopoulos D (2011): Epigenetic aberrations during oncogenesis. Cell Mol Life Sci 68:1681-702. https://doi.org/10.1007/s00018-010-0624-z
  23. Hernandez L, Hsu SC, Davidson B, Birrer MJ, Kohn EC, Annunziata CM (2010): Activation of NFkappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer. Cancer Res 70:4005-4014. https://doi.org/10.1158/0008-5472.CAN-09-3912
  24. Holschneider CH, Berek JS (2000): Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol 19:3-10. https://doi.org/10.1002/1098-2388(200007/08)19:1<3::AID-SSU2>3.0.CO;2-S
  25. Jackson E, Anderson K, Ashwell C, Petitte J, Mozdziak PE (2007): CA125 expression in spontaneous ovarian adenocarcinomas from laying hens. Gynecol Oncol 104:192-198. https://doi.org/10.1016/j.ygyno.2006.07.024
  26. Jair KW, Bachman KE, Suzuki H, Ting AH, Rhee I, Yen RW, Baylin SB, Schuebel KE (2006): De novo CpG island methylation in human cancer cells. Cancer Res 66:682-92. https://doi.org/10.1158/0008-5472.CAN-05-1980
  27. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ (2008): Cancer statistics, 2008. CA Cancer J Clin 58:71-96. https://doi.org/10.3322/CA.2007.0010
  28. Jeong W, Kim HS, Kim YB, Kim MA, Lim W, Kim J, Jang HJ, Suh DH, Kim K, Chung HH, Bazer FW, Song YS, Han JY, Song G (2012): Paradoxical expression of AHCYL1 affecting ovarian carcinogenesis between chickens and women. Exp Biol Med (Maywood) 237:758-767. https://doi.org/10.1258/ebm.2012.011433
  29. Kalluri R, Weinberg RA (2009): The basics of epithelial- mesenchymal transition. J Clin Invest 119:1420-1428. https://doi.org/10.1172/JCI39104
  30. Kuo KT, Mao TL, Jones S, Veras E, Ayhan A, Wang TL, Glas R, Slamon D, Velculescu VE, Kuman RJ, Shih Ie M (2009): Frequent activating mutations of PIK-3CA in ovarian clear cell carcinoma. Am J Pathol 174:1597-1601. https://doi.org/10.2353/ajpath.2009.081000
  31. Kurman RJ, Shih Ie M (2008): Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 27:151-160.
  32. Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih Ie M (2008): Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol 198:351-356. https://doi.org/10.1016/j.ajog.2008.01.005
  33. Laios A, O'Toole S, Flavin R, Martin C, Kelly L, Ring M, Finn SP, Barrett C, Loda M, Gleeson N, D'Arcy T, McGuinness E, Sheils O, Sheppard BJ OL (2008): Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer 7:35. https://doi.org/10.1186/1476-4598-7-35
  34. Lan J, Hua S, He X, Zhang Y (2010): DNA methyltransferases and methyl-binding proteins of mammals. Acta Biochim Biophys Sin (Shanghai) 42:243-252. https://doi.org/10.1093/abbs/gmq015
  35. Lancaster JL, Gosh S, Sethi R, Tripathi S (2006): Can heterotopic gastric mucosa present as globus pharyngeus? J Laryngol Otol 120: 575-578.
  36. Lee JY, Jeong W, Lim W, Kim J, Bazer FW, Han JY, Song G (2012): Chicken pleiotrophin: regulation of tissue specific expression by estrogen in the oviduct and distinct expression pattern in the ovarian carcinomas. PLoS One 7:e34215. https://doi.org/10.1371/journal.pone.0034215
  37. Liliac L, Amalinei C, Balan R, Grigoras A, Caruntu ID (2012): Ovarian cancer: insights into genetics and pathogeny. Histol Histopathol 27:707-719.
  38. Lim W, Kim JH, Ahn SE, Jeong W, Kim J, Bazer FW, Han JY, Song G (2012): Avian SERPINB11 gene: a marker for ovarian endometrioid cancer in chickens. Exp Biol Med (Maywood) 237:150-159. https://doi.org/10.1258/ebm.2011.011250
  39. Liu J, Lin B, Hao Y, Qi Y, Zhu L, Li F, Liu D, Cong J, Zhang S, Iwamori M (2009): Lewis y antigen promotes the proliferation of ovarian carcinoma- derived RMG-I cells through the PI3K/Akt signaling pathway. J Exp Clin Cancer Res 28:154. https://doi.org/10.1186/1756-9966-28-154
  40. Liu JJ, Lin B, Hao YY, Li FF, Liu DW, Qi Y, Zhu LC, Zhang SL, Iwamori M (2010): Lewis(y) antigen stimulates the growth of ovarian cancer cells via regulation of the epidermal growth factor receptor pathway. Oncol Rep 23:833-841.
  41. Lu KH, Yates MS, Mok SC (2009): The monkey, the hen, and the mouse: models to advance ovarian cancer chemoprevention. Cancer Prev Res (Phila) 2:773-775. https://doi.org/10.1158/1940-6207.CAPR-09-0156
  42. Marnett LJ (2000): Oxyradicals and DNA damage. Carcinogenesis 21:361-370. https://doi.org/10.1093/carcin/21.3.361
  43. Murdoch WJ, Van Kirk EA, Alexander BM (2005): DNA damages in ovarian surface epithelial cells of ovulatory hens. Exp Biol Med (Maywood) 230:429-433. https://doi.org/10.1177/15353702-0323006-11
  44. Nam S, Kim B, Shin S, Lee S (2008): miRGator: an integrated system for functional annotation of microRNAs. Nucleic Acids Res 36:D159-164.
  45. Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, Varmus HE (2002): Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 1:53-62. https://doi.org/10.1016/S1535-6108(01)00002-2
  46. Parazzini F, Franceschi S, La Vecchia C, Fasoli M (1991): The epidemiology of ovarian cancer. Gynecol Oncol 43:9-23. https://doi.org/10.1016/0090-8258(91)90003-N
  47. Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales FA, Jones PA (1999): The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 27:2291-2298. https://doi.org/10.1093/nar/27.11.2291
  48. Robinson FE, Etches RJ (1986): Ovarian steroidogenesis during follicular maturation in the domestic fowl (Gallus domesticus). Biol Reprod 35:1096-1105. https://doi.org/10.1095/biolreprod35.5.1096
  49. Rodriguez-Burford C, Barnes MN, Berry W, Partridge EE, Grizzle WE (2001): Immunohistochemical expression of molecular markers in an avian model: a potential model for preclinical evaluation of agents for ovarian cancer chemoprevention. Gynecol Oncol 81:373-379. https://doi.org/10.1006/gyno.2001.6191
  50. Rodriguez GC, Walmer DK, Cline M, Krigman H, Lessey BA, Whitaker RS, Dodge R, Hughes CL (1998): Effect of progestin on the ovarian epithelium of macaques: cancer prevention through apoptosis? J Soc Gynecol Investig 5:271-276. https://doi.org/10.1016/S1071-5576(98)00017-3
  51. Sherman ME (2000): Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 13:295-308. https://doi.org/10.1038/modpathol.3880051
  52. Siegel R, Ward E, Brawley O, Jemal A (2011): Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212-236. https://doi.org/10.3322/caac.20121
  53. Socha MJ, Said N, Dai Y, Kwong J, Ramalingam P, Trieu V, Desai N, Mok SC, Motamed K (2009): Aberrant promoter methylation of SPARC in ovarian cancer. Neoplasia 11:126-35. https://doi.org/10.1593/neo.81146
  54. Song Y, Wu J, Oyesanya RA, Lee Z, Mukherjee A, Fang, X (2009): Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia- inducible factor-1-independent mechanism. Clin Cancer Res 15:492-501. https://doi.org/10.1158/1078-0432.CCR-08-1945
  55. Stakleff KD, Von Gruenigen VE (2003): Rodent models for ovarian cancer research. Int J Gynecol Cancer 13:405-412. https://doi.org/10.1046/j.1525-1438.2003.13317.x
  56. Stammer K, Edassery SL, Barua A, Bitterman P, Bahr JM, Hales DB, Luborsky JL (2008): Selenium-binding protein 1 expression in ovaries and ovarian tumors in the laying hen, a spontaneous model of human ovarian cancer. Gynecol Oncol 109:115-121. https://doi.org/10.1016/j.ygyno.2007.12.030
  57. Thiery JP, Sleeman JP (2006): Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol 7:131-142. https://doi.org/10.1038/nrm1835
  58. Tillmann T, Kamino K, Mohr U (2000): Incidence and spectrum of spontaneous neoplasms in male and female CBA/J mice. Exp Toxicol Pathol 52:221-5. https://doi.org/10.1016/S0940-2993(00)80032-9
  59. Valeri N, Vannini I, Fanini F, Calore F, Adair B, Fabbri M (2009): Epigenetics, miRNAs, and human cancer: a new chapter in human gene regulation. Mamm Genome 20:573-580. https://doi.org/10.1007/s00335-009-9206-5
  60. Vanderhyden BC, Shaw TJ, Ethier JF (2003): Animal models of ovarian cancer. Reprod Biol Endocrinol 1:67. https://doi.org/10.1186/1477-7827-1-67
  61. Vermeulen K, Van Bockstaele DR, Berneman ZN (2003): The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36: 131-149. https://doi.org/10.1046/j.1365-2184.2003.00266.x
  62. Walsh KM, Poteracki J (1994): Spontaneous neoplasms in control Wistar rats. Fundam Appl Toxicol 22: 65-72. https://doi.org/10.1006/faat.1994.1009
  63. Xing D, Orsulic S (2005): A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. Proc Natl Acad Sci U S A 102:6936-6941. https://doi.org/10.1073/pnas.0502256102
  64. Yang X, Fraser M, Moll UM, Basak A, Tsang BK (2006): Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 66:3126-3136. https://doi.org/10.1158/0008-5472.CAN-05-0425
  65. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Giannakakis A, Alexiou P, Hasegawa K, Johnstone CN, Megraw MS, Adams S, Lassus H, Huang J, Kaur S, Liang S, Sethupathy P, Leminen A, Simossis VA, Sandaltzopoulos R, Naomoto Y, Katsaros D, Gimotty PA, DeMichele A, Huang Q, Butzow R, Rustgi AK, Weber BL, Birrer MJ, Hatzigeorgiou AG, Croce CM, Coukos G (2008): Genomic and epigenetic alterations deregulate micro- RNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA 105:7004-7009. https://doi.org/10.1073/pnas.0801615105